Consun Pharmaceutical is the partner-of-choice in China's nephrology market — with mature commercial infrastructure, a next-generation R&D pipeline, and a robust business development engine built to serve kidney patients globally.
Consun is transforming from China's leading nephrology company into an innovation-driven pharmaceutical group — anchored in deep clinical evidence and powered by a next-generation R&D engine.
Over 30 years of effective and safe clinical application benefiting 3 million+ patients. Our core nephrology products are backed by 1,154 publications in leading journals and recommended by 1,000+ KOLs.
11 active western medicine R&D programs including 3 innovative assets, led by a team with 70+ IND/NDA filings, 100+ clinical trials, and FDA breakthrough therapy experience.
TCM pipelines not shown. Source: Company H1 2025 report.
Consun's nephrology business delivered ¥1.88 Bn revenue in 2024 (+28% YoY), driven by robust clinical evidence, scientific leadership, and China's largest dedicated nephrology commercial infrastructure.
Our core nephrology products have over 30 years of clinical application, benefiting more than 3 million patients. With 1,154 publications in leading journals, strategic partnerships with the Chinese Society of Nephrology (CSN) and the World Federation of Chinese Medicine Societies (WFCMS), and recommendations from 1,000+ KOLs, our scientific foundation is unmatched in China's nephrology space.
Core products are listed on both the National Reimbursement Drug List (NRDL) and National Essential Medicine List (NEML) for three consecutive editions, and are strongly recommended by clinical guidelines — ensuring broad accessibility and physician confidence across China.
We are now extending this leadership position internationally and investing in innovative assets to address the full spectrum of kidney disease.
Consun strengthens nephrology leadership while maintaining strong positions in gynecology & pediatrics, imaging agents, and OTC products.
Our R&D leadership team brings 70+ IND/NDA filings, 100+ clinical trials across multiple therapeutic areas, and FDA breakthrough therapy and accelerated approval experience.
Consun began its innovation transformation in 2023 with three strategic pillars: talent acquisition from leading global pharma companies, R&D transformation focusing on innovative first-in-class and best-in-class assets, and global partnering and commercialization capabilities.
Our R&D team spans the full development lifecycle — from pre-clinical and CMC through clinical, regulatory, pharmacovigilance, data management, biostatistics, and quality assurance. Team leaders bring direct experience from companies including Pfizer, Merck, AstraZeneca, Novartis, Fresenius, BMS, and IQVIA.
Four established production sites across Guangzhou, Yulin, Tongliao, and Horgos safeguard manufacturing and supply chain operations with substantial capacity for granules, injections, tablets, capsules, oral solutions, and APIs.
Consun's innovative CKD asset SK-08 has entered Phase I clinical trials, marking a key milestone in the company's innovation transformation.
News list →Nephrology revenue grew 28% YoY to ¥1.88 Bn. Net profit of ¥917M demonstrates strong financial backing for continued innovation investment.
News list →New BD team of MNC background established to facilitate global partnerships, with focused strategy on innovative BIC/fast-follow assets in nephrology.
News list →Consun looks forward to exploring win-win collaborations. With China's largest nephrology commercial infrastructure, a growing innovation pipeline, and a globalized BD team with MNC background, we offer a uniquely compelling platform for kidney disease-focused partnerships.